Horizon plunges deeper into the orphan drug space.
News & Analysis: Raptor Pharmaceutical
Shares pop on rumors of a potential buyout.
This stock is as prone to soaring (and diving) as its name suggests.
Potential buyers abound, but would any of them want to buy Raptor?
This rare-disease drugmaker has some pretty big obstacles to overcome.
Has the biotech beatdown been too harsh on this rare disease drugmaker?
Traders sold-off the company's stock after it reported a mixed quarterly earnings report.
Are these three beaten-down stocks worth a close look? Our contributors think so.
Raptor Pharmaceuticals' shares cratered after a top clinical candidate missed the mark in a mid-stage study.
Raptor Pharmaceuticals shares nosedive after the company announces a substantial cash raise. Find out why Raptor likely made this move, and whether this dip is your opportunity to buy.